Why Affordable Insulin Is a Money Problem, Not a Science Problem – Part 2
What happens when the solution to America’s insulin crisis isn’t a new molecule or fancy delivery device—but a new way of thinking about biotech itself?
Why Affordable Insulin Is a Money Problem, Not a Science Problem – Part 1
What if affordable insulin isn’t a scientific hurdle—but a financial and distribution puzzle no one’s been motivated to solve?
From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 2
Are you struggling with the complexities of cell and gene therapy manufacturing and wondering how automation and digital solutions can truly make these life-saving therapies accessible to more people?
From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 1
Cell and gene therapies have opened the doors to personalized medicine, but manufacturing these complex therapies is filled with hidden process risks that can compromise efficacy and patient access.
Why AI and Automation Tools Won’t Deliver Until Your Lab’s Data Is Connected – Part 2
What separates labs with truly connected, AI-ready data from those drowning in digital chaos?
Why AI and Automation Tools Won’t Deliver Until Your Lab’s Data Is Connected – Part 1
What if the real bottleneck in biotech labs isn’t equipment, talent, or even funding—but a silent issue lurking in plain sight: fragmented data?
How to Stop Defaulting to CHO: An Evidence-Based Host Selection Framework for Biologics
“Will this novel host replace CHO?” I hear this question often — and I want to be direct with you: I think it’s the wrong question.
Why CHO Is Still Winning (and the 5 Platforms That Beat It in Specific Contexts)
Is CHO still the host of choice?
Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 2
Securing capital for biotech innovation has never been more challenging—or more crucial.
Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 1
Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.